2020
Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors.
Barnes JI, Lin JK, Gupta D, Owens DK, Goldhaber-Fiebert JD, Kunz PL. Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. Journal Of The National Comprehensive Cancer Network 2020, 18: 1200-1209. PMID: 32886901, DOI: 10.6004/jnccn.2020.7563.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCost-Benefit AnalysisHumansNeoplasm MetastasisNeuroendocrine TumorsPancreatic NeoplasmsPeptides, CyclicQuality-Adjusted Life YearsRandomized Controlled Trials as TopicSomatostatinSurvival AnalysisConceptsIncremental cost-effectiveness ratioMetastatic enteropancreatic neuroendocrine tumorsEnteropancreatic neuroendocrine tumorsNeuroendocrine tumorsInitial therapyActive surveillanceNCCN Clinical Practice GuidelinesProlonged progression-free survivalProgression-free survivalClinical practice guidelinesActive surveillance strategyLifetime time horizonCost-effectiveness ratioHealthcare sector perspectiveProbabilistic sensitivity analysesCLARINET trialPostprogression treatmentPlacebo armAdrenal tumorsTumor trialsTreatment optionsPractice guidelinesLanreotideSurveillance strategiesQALY
2016
Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors
Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematology/Oncology Clinics Of North America 2016, 30: 163-177. PMID: 26614375, DOI: 10.1016/j.hoc.2015.09.008.Peer-Reviewed Original ResearchMeSH KeywordsDisease-Free SurvivalHumansMolecular Targeted TherapyNeuroendocrine TumorsRandomized Controlled Trials as TopicReceptors, SomatostatinSomatostatinTreatment OutcomeConceptsSomatostatin analoguesNeuroendocrine tumorsRole of SSAsTreatment of NETsPeptide receptor radionuclide therapyMetastatic neuroendocrine tumorsHormone-related symptomsReceptor radionuclide therapyRare epithelial neoplasmLocal therapySymptom managementTumor controlNeuroendocrine differentiationEffective therapyEpithelial neoplasmsDisease CenterPromising treatmentRadionuclide therapyTumor growthTherapyTreatmentTumorsSurgeryNeoplasmsLung
2015
Role of somatostatin analogues in the treatment of neuroendocrine tumors.
Narayanan S, Kunz PL. Role of somatostatin analogues in the treatment of neuroendocrine tumors. Journal Of The National Comprehensive Cancer Network 2015, 13: 109-17; quiz 117. PMID: 25583773, DOI: 10.6004/jnccn.2015.0012.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalHumansNeuroendocrine TumorsRandomized Controlled Trials as TopicReceptors, SomatostatinSomatostatinTreatment OutcomeConceptsNeuroendocrine tumorsSomatostatin analoguesTumor controlTreatment of NETsSystemic tumor controlHormone-related symptomsManagement of patientsRare epithelial neoplasmAdvanced diseaseHormone excessSymptom managementNeuroendocrine differentiationEpithelial neoplasmsGastrointestinal tractPatientsTumorsTreatmentDiarrheaNeoplasmsLungSerotoninSyndromeSymptomsManagementMainstay